Market Access Strategies for Prescription Digital Therapeutics

Market Access Strategies for Prescription Digital Therapeutics

Prescription Digital Therapeutics: Overcoming barriers and achieving market access success

As the operating environment for prescription digital therapeutics (PDT) evolves, manufacturers who want success are challenged to up their market access game to win stakeholder support. The approach they take will shape their market access strategy. So, how can you get payers onside? What are the reimbursement challenges? Where will patients need support? How can you address physicians’ needs? What does an ideal PDT market access team look like? This report explores the challenges and solutions for PDT market access success.

Companies

Sanofi, Biogen, Novo Nordisk, Proteus Digital Health, Omada Health, Verily Life Sciences, Dario, Pear Therapeutics, Boehringer Ingelheim, Biofourmis, Chugai, Click Therapeutics, Happify, Ironwood Pharmaceuticals, Kaia, NightWare, Shionogi, Voluntis, Cognoa, Dthera Sciences, Abbott, BehaVR, Natural Cycles, aidhere GmbH, GAIA AG, Mahana Therapeutics, mynoise GmbH, Rehappy GmbH, Theranica, Vivira Health Lab, e-therapeutics, OpenAI, Otsuka Pharmaceutical, Akili Interactive, Selfapy GmbH, Sympatient GmbH, mementor DE GmbH, Twill, Better Therapeutics, Hideout Health, SilverCloud